Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia, Myeloid, Acute 5Neoplasms 3Carcinoma, Non-Small-Cell Lung 2Recurrence 1Plasmacytoma 1Pathologic Complete Response 1Pancreatic Neoplasms 1Neoplasm Metastasis 1Nasopharyngeal Neoplasms 1Nasopharyngeal Carcinoma 1Myeloid Malignancies 1Myelodysplastic Syndromes 1Multiple Myeloma 1Microsatellite Stable Colorectal Carcinoma 1Lung Neoplasms 1Leukemia, Myelomonocytic, Chronic 1Hematologic Neoplasms 1Hematologic Diseases 1Head and Neck Neoplasms 1Epstein-Barr Virus Infections 1Carcinoma, Ovarian Epithelial 1Breast Neoplasms 1

Interventions

Cyclophosphamide 14fludarabine 12fludarabine phosphate 8Melphalan 8Brentuximab Vedotin 8Whole-Body Irradiation 7Mycophenolic Acid 7Busulfan 7Rituximab 6Tacrolimus 5Lenalidomide 4Etoposide 4isatuximab 3Sirolimus 3Mesna 3Granulocyte Colony-Stimulating Factor 3Dexamethasone 3pembrolizumab 2nilotinib 2dacetuzumab 2Vincristine 2Thiotepa 2Sugars 2Stem Cell Transplantation 2Prednisone 2Peripheral Blood Stem Cell Transplantation 2Patient Reported Outcome Measures 2Ondansetron 2N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide 2Methotrexate 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Hematologic Diseases × cc-486 × Clear all
NCT02494258 2026-04-02

A Study to Evaluate Long-term Safety of CC-486 (Oral Azacitidine) in Subjects With Hematological Disorders

Celgene

Phase 2 Completed
5 enrolled 10 charts
Other hematologic neoplasm

Hematologic Diseases, Neoplasms, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡